Document is current
Any future updates will be listed below
-
Authors
Oyedeji, Charity I. http://orcid.org/0000-0001-5179-7142
Hodulik, Kimberly L.
Telen, Marilyn J. http://orcid.org/0000-0003-3809-1780
Strouse, John J. http://orcid.org/0000-0003-0341-1457
-
Funding
Funding for this research was provided by:
Duke Center for Research to Advance Healthcare Equity (REACH Equity) sponsored by the National Institute on Minority Health and Health Disparities (U54MD012530)
National Institute on Aging Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSTAR) award (1R03AG074054-01)
HRSA for the Education and Mentoring to Bring Access to Comprehensive Care (EMBRACE) Network (U1EMC42461-01)
- License Information
-
More Information
Article History
Accepted: 7 February 2023
First Online: 28 February 2023
Declarations
:
: This study was funded by the Duke Center for Research to Advance Healthcare Equity (REACH Equity), which is supported by the National Institute on Minority Health and Health Disparities under award number U54MD012530 and the National Institute on Aging (NIA) Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSTAR) award number 1R03AG074054-01 to CIO in the preparation of this manuscript. JJS received support from the Health Resources and Services Administration (HRSA) for the Education and Mentoring to Bring Access to Comprehensive Care (EMBRACE) Network (U1EMC42461-01) for the preparation of this manuscript.
: Charity I. Oyedeji has received research funds from the NIA (National Institutes of Health [NIH]). Kimberly L. Hodulik declares that she has no conflicts of interest. Marilyn J. Telen has received research funds from the Doris Duke Charitable Foundation, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the NHLBI (NIH), FDA, Forma Therapeutics, and CSL Behring, and has also served on an Advisory Board for Pfizer, Inc. and a Data Monitoring Committee for Novartis. John J. Strouse receives research funds from the NHLBI, Centers for Disease Control and Prevention (CDC), Takeda, and Agios, and has served on a scientific advisory board on gene therapy for sickle cell disease for Aruvant.
: Not applicable.
: Not applicable.
: Not applicable.
: No datasets were generated or analyzed during the current study.
: Not applicable.
: We certify that all authors have made substantial contributions to all aspects of the work, including conception and planning of the work that led to the manuscript, drafting and/or critical revision of the manuscript, and approval of the final version.
